Systematic analysis of CD39, CD103, CD137 and PD-1 as biomarkers for naturally occurring tumor antigen-specific TILs.

Monika A. Eiva^{1,2,3}, Dalia K. Omran¹, Jessica Chacon⁴, Daniel J. Powell Jr.^{1,2,3},

1. Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.

2. Center for Cellular Immunotherapies, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, United States.

3. Department of Pathology and Laboratory Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States

4. Texas Tech University Health Sciences Center, Paul L Foster School of Medicine and Woody L. Hunt School of Dental Medicine, El Paso, TX, United States

Correspondence should be addressed to D.J.P (poda@penmedicine.upenn.edu)

Daniel J. Powell Jr., PhD

University of Pennsylvania

3400 Civic Center Blvd.

Bldg. 421, TRC Rm 8-103

Philadelphia, PA 19104-5156

Office: 215-573-4783

Fax: 215-573-5129

COI statement: DJP holds a patent on CD137 enrichment for efficient tumor infiltrating lymphocyte selection (U.S. Pat. No. 10,233,425) and receives fees for advisory services from InsTIL Bio on TIL therapy.

Short title: Comparative analysis of T cell biomarkers in human cancer.

Keywords: CD137, tumor-infiltrating lymphocytes, tumor-specific biomarkers, CD103, PD-1, CD39.

Abbreviations: tumor-infiltrating lymphocytes (TILs), confidence interval (CI)

Abstract

The detection of tumor-specific T cells in solid tumors is integral to the interrogation of endogenous antitumor responses and to the advancement of downstream therapeutic applications, such as checkpoint immunotherapy and adoptive cell transfer. A number of biomarkers are reported to identify endogenous tumor-specific tumor infiltrating lymphocytes (TILs), namely CD137, PD-1, CD103, and CD39, however a direct comparison of these molecules has yet to be performed. Here, we evaluate these biomarkers in primary human high-grade serous ovarian tumor samples using single-cell mass cytometry to characterize and compare their relative phenotypic profiles, as well as their response to autologous tumor cells *ex vivo*. CD137+, PD-1+, CD103+, and CD39+ TILs are all detectable in tumor samples with CD137+ TILs being the least abundant. PD-1+, CD103+, and CD39+ TILs all express a subset of CD137+ cells, while CD137+ TILs highly co-express the aforementioned markers. CD137+ TILs exhibit the highest expression of cytotoxic effector molecules, such as IFN γ and Granzyme B, compared to PD-1+, CD103+ or CD39+ TILs. Removal of CD137+ TILs from PD-1+, CD103+, or CD39+ TILs results in lower secretion of IFN γ in response to autologous tumor stimulation, while CD137+ TILs highly secrete IFN γ in an HLA-dependent manner. CD137+ TILs exhibited an exhausted phenotype with CD28 co-expression, suggestive of antigen recognition and receptiveness to reinvigoration via immune checkpoint blockade. Together, our findings demonstrate that the antitumor abilities of PD-1+, CD103+, and CD39+ TILs are mainly derived from a subset of TILs expressing CD137, implicating CD137 is a more selective biomarker for naturally occurring tumor-specific TILs.

50 Introduction

51 The intratumoral abundance of tumor-infiltrating lymphocytes (TILs) is a positive
 52 prognostic factor for increased survival in most solid cancers, indicating that TILs are integral
 53 to endogenous antitumor immunity and play a role in controlling cancer progression^{1,2}.
 54 However, only a small percentage of TILs respond against tumor antigens and their antitumor
 55 response can be hindered by multiple mechanisms of immunosuppression^{3,4}. The challenges
 56 of detecting TILs capable of responding to tumor antigens has led to great interest in
 57 identifying biomarkers of tumor-specific TILs in solid tumors. Biomarkers that identify tumor-
 58 specific TILs are integral for downstream applications, such as enriching tumor-specific TILs
 59 for use in adoptive cellular therapy, investigating endogenous antitumor immunity, studying
 60 mechanisms of effective immunotherapy, identifying antigen-specific T-cell receptors or
 61 neoantigens, and exploring the immunobiology of these cells^{5–8}. The need for effective
 62 biomarkers to detect T cells is further underscored by the fact that many cancers, such as
 63 ovarian cancer, do not have well-defined shared tumor-specific antigens capable of initiating a
 64 tumor-specific T cell response. The lack of shared tumor-specific antigens is in contrast to
 65 other cancers, such as melanoma, where some patients mount spontaneous responses
 66 against the melanocyte differentiation antigen, MART-1, which can be used to rapidly identify
 67 tumor-specific T cells in melanoma patients using peptide/MHC detection agents⁹.
 68 Furthermore, many cancers including ovarian cancer, have limited numbers of T cells that
 69 naturally respond to tumor-specific antigens, making their examination challenging. Identifying
 70 robust biomarkers for tumor-specific TILs can address this issue.

71 Various biomarkers are used to detect endogenous tumor-specific T cells from solid
 72 tumors, such as the co-stimulatory receptor CD137 (also known as 4-1BB and TNFRSF9), the
 73 negative immunoregulatory receptor PD-1, the lymphocyte-retention mediating integrin CD103,

and the co-expression of both the ectonucleotidase CD39 and CD103^{10–13}. Identifying a singular, accurate biomarker for tumor-specific TILs would streamline downstream research and clinical applications, but it is unknown which singular biomarker is most effective at identifying the tumor-specific TIL subset, as a direct comparison of these reported biomarkers has not been performed. Addressing this knowledge gap is particularly important, because TILs frequently co-express these markers and each biomarker can be differentially expressed across the TIL population, therefore, a biomarker comparison is needed to identify the marker that most accurately discerns tumor-specific TILs^{14,15}.

Here, we compared the expression of CD137, PD-1, CD103 and CD39 on TILs in human ovarian cancer, as these are leading biomarkers used to identify tumor-specific TILs. We hypothesized that a comparative interrogation of TILs in human tumors would reveal which biomarker is most discriminating for tumor-specific TILs with autologous antitumor activity.

Materials and methods

Tumor Samples. Viably frozen, human high-grade serous ovarian tumor samples were purchased from the Penn Ovarian Cancer Research Center (OCRC) Tumor BioTrust Collection. Ethics statement: All donor samples used in this study were de-identified and approved for use by the UPenn Institutional Review Board (IRB 702679, UPCC 17909). Sex and weight are not a biological variable as all tumor samples are from females. As samples are de-identified, age and weight are not known. Surgically resected tumors were procured from the operating room in an aseptic manner. Tissue was mechanically processed into fragments and added to an enzyme digest solution. A 10X stock solution of the enzyme digest buffer contains 2 mg/ mL collagenase (Sigma Aldrich) and 0.3kU/mL DNase I Type IV (Sigma Aldrich); solution was diluted to a 1x solution with RPMI 1640 at time of digestion. Tissue was

incubated in the enzyme digest buffer overnight at room temperature on a rotator. Dissociated tumor tissue was subsequently filtered through sterile 100µm nylon mesh, centrifuged, and washed twice with dPBS (Dulbecco's Phosphate Buffered Saline). Resultant tumor cell digests were cryopreserved in 10% dimethyl sulfoxide (DMSO) (Sigma Aldrich) and human serum (Valley Biomedical, Inc., Product #HS1017). Samples were frozen at -80C and banked at -150C until further use.

Mass Cytometry staining. CyTOF antibodies were bought from Fluidigm as pre-conjugated metal tagged antibodies or were conjugated in-house using the Maxpar Fluidigm kit and protocol. All antibodies were titrated to determine optimal concentrations for staining samples. The panel used to initially investigate tumor-specific markers, before inclusion of CD39 in the aforementioned panel, had the following surface markers: CD3, CD45, CD4, CD8, CD244, CD69, OX40, Lag-3, CD103, Tim-3, TIGIT, PD-1, CD137, CD28, CD127, CD27, GITR, CD25, HLA-DR, and CD160. Intracellular antibodies included: CTLA-4, pStat5, IL-17A, IL-2, IFNγ, Granzyme B, Ki67, and Perforin. We subsequently designed a panel to include CD39 and all other tumor-specific markers of interest. The following panel included CD39 and was used for downstream viSNE, metaPhenoGraph, and biaxial analysis. Anti-human surface markers for the panel were: CD3, CD45, CD4, CD8, CD103, PD-1, OX40, CD39, CD69, CD25, CD137, CD27, Tim-3, CD127, CD28, CD244, CD5, Lag-3, TIGIT, HLA-DR, and CD160. Intracellular markers included: Ki67, IL-17A, IL-2, IFNγ, IL-6, Perforin, pStat5, TNFα, Granzyme B, CTLA-4, and EOMES. The initial panel to compare CD39 and CD137 positive TILs had the following surface antibodies interrogated: CD3, CD45, CD4, CD8, CD137, CD39, CD25, HLA-DR, and CD127. Intracellular antibodies detected for were: IL-2, pStat5, EOMES, T-bet, IL-17A, IFNγ, Granzyme B, Ki67, and Perforin. The last panel used in this study was designed to focus on

122 TIL exhaustion. Surface antibodies used were: CD3, CD45, CD4, CD8, OX40, CD103, TIGIT,
123 CD137, CD39, CD25, CD3, HLA-DR, and CD127. Intracellular antibodies were: IL-2, pStat5,
124 EOMES, T-bet, and Ki67. For all panels, cell identifier stain Iridium191/193, live identifier
125 127IdU (Fluidigm) were used. To discriminate dead cells, cisplatin purchased from Fluidigm or
126 dead stain maleimido-mono-amine-DOTA (mm-DOTA) from Macrocyclics was used. Viably
127 frozen ovarian human tumor digests were stained for CyTOF following the same methodology
128 as Bengsch et al., 2018 ¹⁶. Data acquisition was performed on a CyTOF Helios (Fluidigm
129 CyTOF Helios Mass Cytometer, RRID:SCR_019916) by the CyTOF Mass Cytometer Core at
130 UPenn. The core performed bead-based normalization for all samples.

131

132 **Fluorescent-Activated Cell Sorting:**

133 Tumor samples were thawed and washed twice with staining buffer (phosphate-buffered
134 saline, 5% fetal bovine serum) to remove DMSO. Samples were subsequently stained with
135 Zombie aqua (BioLegend Cat# 423102) for 10 minutes to discriminate live and dead cells.
136 Samples were washed twice to remove Zombie aqua, then incubated at 4°C for 30 minutes in
137 50ul of an antibody cocktail to label human surface markers. Following surface staining,
138 samples were washed three times. Samples were sent to the Flow Cytometry Facility at the
139 Wistar Institute for fluorescent-activated cell sorting (FACS) on a MoFlo Astrios or to the Flow
140 Cytometry Core at the Children's Hospital of Philadelphia and sorted on an Aria. All antibodies
141 were purchased from BioLegend. For all analyses, singlets were detected using FSC-H versus
142 FSC-A followed by SSC-H versus SSC-A. Cells negative for Zombie aqua, were identified as
143 live cells. Anti-human-anti-CD3-PerCpCy5.5 (BioLegend Cat# 317336, RRID:AB_2561628)
144 was used to detect T cells and the following anti-human antibodies were used to identify T cell
145 subsets: anti-CD137-PeCY7 (BioLegend Cat# 309818, RRID:AB_2207741), anti-CD103-

146 BV605 (BioLegend Cat# 350218, RRID:AB_2564283), anti-CD39-APC (BioLegend Cat#
147 328210, RRID:AB_1953234), and anti-PD-1-APCCy7 (BioLegend Cat# 329922,
148 RRID:AB_10933429).

149

150 **Mass cytometry biaxial analyses.** Traditional biaxial analysis, on bead-normalized fcs files,
151 was performed using Flowjo V10 software (FlowJo, RRID:SCR_008520). Intact single cells
152 were identified using event-length and Iridium. Cells were live-gated according to 127IdU and
153 mm-DOTA, where dead cells are positive for mm-DOTA. CD3 and CD45 positivity identified T-
154 cells. Sequential gating analysis was performed for all analyzed markers. The resulting values
155 were used to determine population frequencies.

156

157 **viSNE, and metaPhenoGraph analyses**

158 High-dimensional analysis was conducted using the algorithm viSNE, which uses the Barnes-
159 Hut t-SNE (bh-SNE) implementation, from *cyt* a visualization tool written in Matlab (R2016b,
160 MATLAB,RRID:SCR_001622) downloaded in 2015 and available at
161 <https://www.c2b2.columbia.edu/danapeerlab/html/cyt-download.html>. Live, single,
162 CD3⁺CD45⁺CD137^{+/-} exported fcs data from five donor samples were imported into *cyt*,
163 arcsinh5-transformed, and run as described by Amir et al., 2013¹⁷ to create viSNE plots. The
164 following parameters were used for bh-SNE mapping analysis: Ki67, IL-17A, IL-2, IFN γ ,
165 CD103, PD-1, IL-6, OX40, CD39, Perforin, CD69, CD4, CD8, pStat5, TNFa, GITR, CD25,
166 Granzyme B, CD137. The PhenoGraph algorithm was run, as described by Levin et al., 2015
167¹⁸, with a nearest neighbor input of k=30 and a Euclidean distance metric. Markers used for
168 PhenoGraph clustering were the following: Ki67, IL-17A, IL-2, IFN γ , CD103, PD-1, IL-6, OX40,
169 CD39, Perforin, CD69, CD4, CD8, pStat5, TNFa, GITR, CD25, Granzyme B, CD137.

170 PhenoGraph was metaclustered, as described by Levine et al., 2015, using a k=15 and a
171 Euclidean distance metric. viSNE, PhenoGraph, metaPhenoGraph plots and heatmaps were
172 created by *cyt*.

173

174 **Co-culture experiment.** The following T cell subsets were FACS sorted from patient tumor
175 samples: CD137⁺, CD39⁺CD137⁻, CD103⁺CD137⁻, and PD-1⁺CD137⁻ using the BioLegend
176 antibodies specified in the FACs sorting section. T cells were rested overnight in media. CD45⁺
177 cells were depleted from the same patient sample to obtain CD45⁻ cells for co-culture using the
178 EasySep Human CD45 Depletion Kit from StemCell Technologies Cat# 17898. T cell subsets
179 were co-cultured, with 10ug/ml HLA-blocking Class I (BioLegend Cat# 311402,
180 RRID:AB_314871) & II (BioLegend Cat# 361702, RRID:AB_2563139) or isotype (BioLegend
181 Cat# 400202) antibodies, at a 1:2 ratio of T cells to autologous tumor cells in 100ul of media in
182 a 96-ubottom plate. Following 24hrs co-culture, samples were spun down at 1300rpm, and
183 supernatants were collected and frozen at -80C. To analyze cytokines within the supernatants,
184 the manufacture's protocol of the LEGENDplex Human CD8/NK Panel kit (BioLegend Cat#
185 740267) was followed, and two technical replicates were analyzed per sample.

186

187 **Statistical analysis.** The Student's two-tailed, paired t-test was run to determine statistical
188 significance. NS represents a p-value >0.050, (*) represents a p-value ≤0.050, (**) represents
189 a p-value <0.01, (***) represents a p-value < 0.001, (****) represents a p-value < 0.0001, error
190 bars represent 95% Confidence Interval.

191

Results

A subset of TILs express effector molecules.

To investigate the phenotype of TILs harbored within infiltrated tumors, the algorithms viSNE and PhenoGraph metaclustering^{17,18} were used to co-map CD3⁺CD45⁺ TILs in enzyme-digested ovarian tumors analyzed by single-cell mass cytometry. To address patient-specific variability and to understand TIL dynamics shared between samples, PhenoGraph clusters were merged using the metaclustering algorithm in the interactive cyt tool¹⁷. Metaclustering analysis identified seven major TIL populations (**Figure 1A**). Metaclusters (MCs) 1, 5, 6, and 7 were generally conserved among all samples tested, while MCs 2, 3, and 4 had greater variability (**Figure 1B**). MC5 (mean= 1.51, 95% CI= -0.37 to 3.39) and MC6 (mean= 2.21, 95% CI= -0.83 to 5.24) were the rarest subsets in all samples, and MC5 was consistently enriched for cells expressing activation, proliferation and effector molecules (**Figure 1B,C**). Compared to the other metaclustered groups, only MC5 highly expressed effector molecules associated with antitumor responses, including IL-2, IFN γ , perforin, TNF α , and Granzyme B (**Figure 1C**).

A series of activation-associated, cell surface markers have recently been described to identify, characterize and utilize naturally-occurring tumor-specific T cells in human tumors. CD137, PD-1, CD103, and CD39 are most commonly utilized as biomarkers of TILs with tumor-specificity^{10–13,19}. MC5, which highly expresses effector molecules, was enriched for TILs expressing high levels of CD137 as well as the co-stimulatory receptor OX40, another TNFR family member upregulated upon T cell activation. MC5 moderately expressed CD103, PD-1, and CD39, as well as activation markers CD69 and CD25 (**Figure 1D**), indicating that cells in MC5 are enriched for an activated T cell population.

215 **CD137⁺ TILs preferentially express effector molecules and co-express biomarkers of** 216 **tumor-specificity.**

217 To gain a further understanding of which biomarkers are most selective in identifying
218 TILs expressing effector molecules within human cancer, we examined viSNE plots of
219 activation and tumor-specific biomarkers, which revealed the heterogeneity of their expression
220 patterns. Similar to what was observed in the metaPhenoGraph heat map results (**Figure 1D**),
221 CD137 expression was primarily detected in the MC5 region, was expressed by both CD4⁺ and
222 CD8⁺ TILs, and had co-expression of OX40, CD103, CD39, and PD-1 (**Figure 2A**). PD-1 and
223 CD69 expression was common, broadly distributed, with overlapping expression of CD25,
224 OX40, CD103, CD39, and CD137. CD25 and OX40 expression was dominated by CD4⁺ TILs
225 and commonly co-expressed with CD39, while CD103⁺ TILs were mainly CD8⁺, a portion of
226 which expressed CD39. Overall, few TILs expressed effector molecules, such as IFN γ , IL-2,
227 and TNF α , and their MMI was low, compared to the level of activation and tumor-specific
228 biomarkers. However, the few TILs that expressed effector molecules such as IFN γ , IL-2, and
229 TNF α , were positive for CD137 in the MC5 region, suggestive of CD137⁺ TIL polyfunctionality,
230 and CD137 expression was most focal than other tumor-specific biomarkers (**Figure 2A**).

231 Since viSNE plot analyses indicated that CD137 expression overlapped more with
232 effector molecule expression than other biomarkers, we compared effector molecule
233 expression within the CD137⁺ TIL population to expression in TILs expressing other tumor-
234 specific and activation markers (**Supplementary Figure 1**). Generally, CD137⁺ TILs exhibited
235 the greatest frequency of cells expressing IFN γ , TNF α , Granzyme B, perforin and IL-2,
236 compared to other biomarker expressing TILs (**Figure 2B**). CD137⁺ TILs had greater
237 expression of IFN γ (p-value = 0.0008), Granzyme B (p-value = 0.01), perforin (p-value = 0.003),
238 and IL-2 (p-value = 0.002) than CD103⁺ TILs, but similar levels of TNF α expression (**Figure**

239 **2B).** CD137⁺ TILs and OX40⁺ TILs were similar with the exception of CD137⁺ TILs expressing
 240 greater frequencies of IFN γ (p-value = 0.008) and Granzyme B (p-value = 0.01) (**Figure 2B**).
 241 While this study focuses on comparing single biomarkers, dual expression of CD103⁺CD39⁺
 242 was reported to identify CD8⁺ tumor-specific TILs ¹³. When comparing CD103⁺CD39⁺ TILs to
 243 CD137⁺ TILs, CD137 expression was more selective for identifying total CD3⁺ and CD8⁺ TILs
 244 expressing effector molecules (**Supplementary Figure 2 A,B**) with no differences observed
 245 when comparing CD4⁺ TILs (data not shown).

246 Although CD137⁺ TILs exhibited the highest expression of effector molecules, the
 247 frequency of these cells was low (mean =4.1%, 95% CI =1.87 to 6.36) compared to TILs
 248 expressing other biomarkers (**Figure 3A**). Since viSNE and PhenoGraph analyses (**Figure 1**)
 249 revealed that CD137⁺ TILs often co-express tumor-specific biomarkers, we next examined the
 250 frequency of CD137⁺ TILs within TIL populations expressing other tumor-specific biomarkers
 251 using biaxial gating (**Figure 3B**). CD137⁺ TILs commonly co-expressed PD-1 (54.9% 95%
 252 CI=39.47 to 70.31]), CD103 (mean = 37.6%, 95% CI=24.64 to 48.78), and CD39 (mean =
 253 76.8%, 95% CI=64.55 to 88.95). In contrast, only a small portion of PD-1⁺ (mean = 6.2%, 95%
 254 CI=4.36 to 8.07), CD103⁺ (mean = 6.2%, 95% CI= 3.13 to 9.17), or CD39⁺ (mean = 6.7%, 95%
 255 CI=3.45 to 10.02) TILs co-expressed CD137. These results, combined with effector molecule
 256 expression data (**Figure 2**), indicate that CD137 is the more selective marker for identifying
 257 tumor-specific TILs (**Figure 3C**).

258 **CD137⁺ TILs are the subset of PD-1⁺, CD103⁺, and CD39⁺ TILs that express effector**
 259 **molecules and exhibit antitumor activity.**

260 We next investigated whether the CD137⁺ TIL subset contained within other biomarker
 261 populations are enriched for effector molecules. Decreased IFN γ expression was observed in
 262 CD39⁺ (p-value = 0.001), CD103⁺ (p-value< 0.001), and PD-1⁺ (p-value= 0.002) TILs when

CD137⁺ TILs were selectively gated out (**Supplementary Figure 2C**) prior to analysis in **Figure 4A**. This effect was also observed in TILs expressing CD25 (p -value= 0.001), CD69 (p -value= 0.001), or OX40 (p -value= 0.003) (**Figure 4A**). Granzyme B expression similarly decreased (**Figure 4B**), leading us to hypothesize that the CD137⁺ TIL subset may account for the reactivity observed in other biomarker-expressing tumor-specific TIL populations^{10–13}.

We next tested whether functional reactivity of TILs was restricted to the CD137⁺ TIL subset in co-culture assays where CD137⁺ TILs were first sorted out of the bulk TIL, and then other biomarker expressing TIL subsets were sorted prior to co-culture with autologous tumor cells (**Supplementary Figure 2D**). Compared to the PD-1⁺, CD103⁺ and CD39⁺ TIL populations depleted of CD137⁺ cells, the CD137⁺ TIL subset produced the highest levels of IFN γ in response to autologous tumor cells exposure in three independent donor samples. Production of IFN γ by CD137⁺ TILs upon autologous tumor co-culture was HLA-dependent, as IFN γ decreased upon HLA blocking of MHC class I and class II with antibodies (**Figure 4C**). In all tested TIL samples, the CD137⁺ subset secreted IFN γ levels twice as high as that of unstimulated TILs alone. These results indicate that effector molecule expression is enriched within the CD137⁺ TIL fraction, and that CD137⁺ TILs account for the majority of antitumor reactivity observed within PD-1⁺, CD39⁺ and CD103⁺ TIL populations.

Both CD4⁺ and CD8⁺ TILs express markers of antitumor reactivity.

Having analyzed co-expression and effector profiles of tumor-specific marker expressing populations within overall CD3⁺CD45⁺ TILs, we next examined the biomarker profiles of CD4⁺ or CD8⁺ TIL subsets in ovarian cancer samples. There were more CD4⁺ TILs (mean = 49.6% , 95% CI=43.43 to 55.86) than CD8⁺ TILs (p -value = 0.02, mean = 34.9%, 95% CI=27.88 to 41.85) (**Figure 5A**). CD137 expression was similar in the CD4⁺ and CD8⁺ TIL subsets, suggesting that both CD4⁺ and CD8⁺ T cells are important to antitumor activity in

ovarian cancer. More CD8⁺ TILs expressed CD103 (p -value <0.001) and CD69 (p -value = 0.01). A higher percentage of CD4⁺ TILs expressed CD25 (p -value <0.001) and OX40 (p -value = 0.01), but there was no significant differences in CD39 or PD-1 expression (**Figure 5B**). When comparing effector molecule expression, an increased frequency of IFN γ (p -value = 0.04), TNF α (p -value = 0.01), and IL-2 (p -value = 0.01) expressing cells was detected in CD4⁺ TILs. CD8⁺ TILs contained greater frequencies of cells expressing Granzyme B (p -value = 0.03), and no difference was detected in perforin expression (**Figure 5C**). These results support the notion that both CD4 and CD8⁺ TILs can express effector molecules, which can be divergent and together may play integral roles in immune responses against tumor cells.

Tumor-specific TILs display a phenotype indicative of restorable exhaustion.

Since our findings indicate that CD137⁺ TILs express effector molecules and other molecules indicative of activation, we queried whether these tumor-specific TILs displayed features of exhaustion, which is commonly associated with chronic tumor-antigen stimulation²⁰. We examined to what degree TILs in meta-cluster 5 (MC5) (**Figure 1,2**), which harbored the highest frequency of CD137⁺ and effector molecule expressing TILs, exhibit hallmarks of exhaustion. The MC5 population expressed multiple markers indicative of activation and/or exhaustion (**Figure 6A**). MC5 TILs expressed PD-1, albeit at overall lower levels than MC6. MC5 TILs uniquely co-expressed PD-1 and the costimulatory molecule CD28, whose signaling is required for rescue of CD8⁺ T cell activity in anti-PD-1 therapy for cancer ²¹. Activation/exhaustion associated marker expression in CD137⁺ TILs was compared to other TIL populations by examining TIGIT, EOMES, and CD39 expression in CD137⁺ or CD137⁻ subsets. CD137⁺ TILs expressed higher levels of the exhaustion-associated markers TIGIT (p -value <0.001), EOMES (p -value <0.001), and CD39 (p -value <0.001), compared to CD137⁻ TILs (**Figure 6B**). Since the aforementioned markers can be upregulated by both activated and

exhausted T cells, we assessed whether CD137⁺ TILs are skewed towards a EOMES^{hi}T-bet^{dim} phenotype associated with dampened effector functions ²² or toward a more functional EOMES^{dim}T-bet^{hi} phenotype. CD137⁺ TILs were more skewed towards an EOMES^{hi}T-bet^{dim} (*p*-value = 0.004) phenotype than their CD137⁻ counterparts, supporting the notion that CD137⁺ TILs are exhausted (**Figure 6C, D**). As CD137⁺ TILs appear exhausted but also harbor tumor-specific TILs that express effector molecules and co-express CD28, our results suggest that CD137⁺ TILs have the greatest potential for reinvigoration ²¹.

Discussion

TILs are a heterogeneous population of immune cells that can differ in specificity, differentiation, and function. Biomarkers that identify endogenous tumor-specific TIL subsets are fundamental to immunobiology research, studying mechanisms of endogenous antitumor immunity, isolating tumor-specific T-cell receptors, and optimizing cellular therapies^{5–8}. We observed that TILs expressing effector molecules often co-expressed other biomarkers used to identify tumor-specific TILs. Earlier studies of TILs expressing a single biomarker reported levels of secondary biomarker co-expression, but a direct comparison between various biomarker-expressing TIL subsets had yet to be conducted^{10–13}. We found that a small subset of PD-1⁺, CD103⁺, and CD39⁺ TILs reproducibly co-express CD137. In contrast, most CD137⁺ TILs highly co-express the aforementioned biomarkers, and preferentially express effector molecules, indicating that CD137 more selectively identifies tumor-specific TILs. Further, removing CD137⁺ TILs from other biomarker-expressing TIL subsets reduced their functional activity in response to autologous tumor stimulation, indicating that while PD-1, CD103, and CD39 markers can be used to identify tumor-specific TILs, CD137 expression is a more discriminatory tumor-specific TIL biomarker.

The finding that CD137 expression is a highly selective marker for endogenous tumor-specific TIL identification is supported by previous findings from our lab¹⁰ [9], and later studies that used CD137 to enrich tumor-specific TILs^{7,10,23}. Our findings contradict results reported by Gros and colleagues showing that both PD-1⁺ and CD137⁺ TIL subsets were tumor-reactive but with PD-1 better identifying tumor-reactive T cells¹¹. Interesting, activation induced expression of CD137 was used to define tumor-reactivity in many of the assays used. The discrepancy between our findings and those reported by Gros et al. may be explained by differences in the cancer type studied as well as the methodology applied. Gros et al. solely

focused on CD8⁺ TILs and did not include CD4⁺ TILs. In contrast, the present study, and our previous study that first defined CD137 as a biomarker for tumor-specific TILs¹⁰ included CD4⁺ TILs in the analysis. This alone does not account for the discrepancy, since CD137 still served as a better biomarker for tumor-specific CD8⁺ TILs. Identifying endogenous tumor-antigen specific TIL biomarkers in patients has been heavily CD8⁺ T-cell-centric^{11–13,24}, but there is growing appreciation for the role of CD4⁺ T cells in promoting antitumor immunity and immunotherapy efficacy^{25–28}. This is emphasized by our findings that CD4⁺ TILs dominate the ovarian tumor digest environment and have equivalent expression of CD137 as CD8⁺ TILs. Also, with the exception of Granzyme B, CD4⁺ TILs had either equivalent or greater positivity for IFN γ , TNF α , perforin, and IL-2. Our results support the idea that both CD8⁺ and CD4⁺ TILs have integral roles in driving antitumor immune responses and may have divergent antigen-specific responses.

A separate study by Duhon et al. demonstrated that co-expression of CD39 and CD103 TILs can identify tumor-specific TILs within solid tumors. Similar to Gros, *et al.*, the work focused on CD8⁺ TILs¹³. Supporting our finding that CD137⁺ TILs often co-express other commonly used tumor-specific TIL biomarkers, both Gros *et. al* and Duhon *et. al*, used CD137 upregulation as a measure to assess tumor-cell recognition by PD-1⁺ or CD39⁺CD103⁺ CD8⁺ TILs in co-culture experiments. Notably, only a subset of enriched PD-1⁺ or CD39⁺CD103⁺ CD8⁺ TILs upregulated CD137 expression after autologous tumor recognition. Unlike Gros *et. al* and Duhon *et. al* studies, we examined TILs from tumor digests without addition of cytokines, establishment of T cell clones, or bulk-expansion. It bears consideration that this methodology can better preserve TIL natural reactivities to autologous tumor antigens with minimal manipulation of TIL biomarker expression.

Immune checkpoint blockade has shown great promise in numerous solid tumors, and successful antitumor responses are thought to rely upon reinvigorated responses by tumor-specific T cells^{20,29,30}. The phenotypic profile of CD137⁺ TILs suggests that they have potential for reinvigoration via checkpoint blockade. CD137⁺ TILs highly expressed multiple co-inhibitory receptors, including PD-1, and were skewed towards a phenotype characteristic of exhausted T cells²² and co-expressed CD28. Expression of CD28 by CD137⁺ TILs is important because restoring exhausted T cell function is dependent on CD28 co-stimulation^{21,31}. However, many cancers, including ovarian cancer, have low response rates to PD-1/PDL1 blockade³². Our data may suggest that one potential explanation is that most patients have too few CD137⁺ TILs to reinvigorate for an effective antitumor response. It is intriguing to hypothesize that the response rate to PD-1/PDL1 blockade may be increased by promoting CD28 signaling to TILs, such as through CTLA-4 blockade. Both CTLA-4 and CD28 bind to CD80 and CD86 on antigen-presenting cells, but CTLA-4 binds CD80 and CD86 with greater affinity and avidity than CD28, enabling it to outcompete CD28 for these ligands. The response rate to anti-PD-1 antibody treatment in ovarian cancer nearly triples when a CTLA-4 blocking antibody is added to the treatment regimen³⁷. Furthermore, agonizing CD137 may aid in promoting antitumor responses in patients, and although CD137 agonism in the clinic has had toxicities^{33,34}, dual bispecific antibodies that agonize CD137 are being developed in order to enhance T cell proliferation and antitumor activity in human cancer without the safety limitations observed in the clinic^{35,36}. The recently developed CD137/OX40 bispecific antibody³⁵ may be promising to test in an ovarian cancer model, as we observed that effector molecule expressing CD137⁺ TILs also co-expressed OX40 (**Figure 2A**). Future studies are needed to determine if CD137⁺ TILs are reinvigorated by anti-PD-1 therapy, whether they

require CD28 signaling, and how they contribute to successful immune checkpoint blockade monotherapy or combinatorial immunotherapy strategies^{35,36}.

Collectively, this work clarifies the differential expression of biomarkers for tumor-specific TILs and demonstrates that CD137 is a more selective biomarker for identifying naturally occurring, tumor-specific TILs than PD-1, CD103, or CD39 within human tumors. We acknowledge there are limitations to this analysis. Our study entirely used ovarian cancer specimens, and results may differ in other cancer types. Also, due to limited cell numbers, we were unable to independently test CD4⁺ and CD8⁺ TILs for TIL subset reactivity, or test restorable exhaustion on PD-1⁺ T cells. Furthermore, PD-1 blockade has low efficacy in *in vitro* assays, and would require sophisticated *in vivo* models and large cell numbers. Nevertheless, we conclude that this work disentangles the differential expression of tumor-specific biomarkers by TILs and identifies CD137 is an ideal singular biomarker for identifying tumor-specific TILs, which provides a deeper understanding of human TILs that may pave a route towards improving immunotherapeutic strategies for cancer.

Authors' Contributions: Conceptualization, methodology, project administration, writing, M.A.E. and D.J.P; Supervision and resources, D.J.P. Funding Acquisition. D.J.P and J.C. Formal analysis, visualization, investigation, validation, M.A.E.; Resources and writing, D.K.O.; Writing-review & editing, J.C.

Funding: This work was supported in part by the NIH/NCI grant P50CA228991, and partly by BMS grant CA186-113. The funding sources had no role in the design, collection, analysis, interpretation, writing, or decision to submit the manuscript for publication.

419 **Acknowledgements:** The authors acknowledge the Ovarian Cancer Translational Center for
 420 Excellence in the Abramson Cancer Center for support of tumor banking operations through
 421 the Tumor BioTrust Collection. The authors thank Dr. Bertram Bengsch and the E. John
 422 Wherry laboratory at the University of Pennsylvania, for aid in the development of CyTOF
 423 antibody panels and insights on data analysis, as well Takuya Ohtani of the UPenn CyTOF
 424 Core for running mass cytometry samples. The authors also acknowledge the personnel of the
 425 Wistar Institute's Flow Cytometry Facility and the Flow Cytometry Core Laboratory at the
 426 Children's Hospital of Philadelphia Research Institute for their aid and expertise in sorting cells.

References

1. Zhang, L. *et al.* Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. (2003) doi:10.1056/NEJMoa020177.
2. Geng, Y. *et al.* Prognostic Role of Tumor-Infiltrating Lymphocytes in Lung Cancer: a Meta-Analysis. *Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol.* **37**, 1560–1571 (2015).
3. Chen, M.-L. *et al.* Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 419–424 (2005).
4. Rabinovich, G. A., Gabrilovich, D. & Sotomayor, E. M. Immunosuppressive strategies that are mediated by tumor cells. *Annu. Rev. Immunol.* **25**, 267–296 (2007).
5. Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A. & Dudley, M. E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. *Nat. Rev. Cancer* **8**, 299–308 (2008).
6. Yossef, R. *et al.* Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy. *JCI Insight* **3**,.
7. Parkhurst, M. *et al.* Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression. *Clin Cancer Res* **23**, 2491–2505 (2017).
8. Leung, W. & Heslop, H. E. Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR. *Cancer Immunol. Res.* **7**, 528–533 (2019).
9. Ramirez-Montagut, T. *et al.* Melanoma antigen recognition by tumour-infiltrating T lymphocytes (TIL): effect of differential expression of Melan-A/MART-1. *Clin. Exp. Immunol.* **119**, 11–18 (2000).

10. Ye, Q. *et al.* CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. *Clin Cancer Res* **20**, 44–55 (2014).
11. Gros, A. *et al.* PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. *J Clin Invest* **124**, 2246–59 (2014).
12. Djenidi, F. *et al.* CD8+CD103+ Tumor-Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients. *J. Immunol.* **194**, 3475–3486 (2015).
13. Duhén, T. *et al.* Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. *Nat. Commun.* **9**, 2724 (2018).
14. Kamada, T. *et al.* PD-1⁺ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. *Proc. Natl. Acad. Sci.* **116**, 9999–10008 (2019).
15. Lowther, D. E. *et al.* PD-1 marks dysfunctional regulatory T cells in malignant gliomas. *JCI Insight* **1**, (2019).
16. Bengsch, B. *et al.* Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. *Immunity* **48**, 1029-1045.e5 (2018).
17. Amir, E. D. I-AD *et al.* viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. *Nat Biotechnol* **31**, 545–52 (2013).
18. Levine, J., Simonds, E., Bendall, S. & Davis, K. Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis. (2015).
19. Lee, Y., Park, J., Park, S.-H. & Shin, E.-C. CD39+CD8⁺ T cells exhibit a distinct phenotype among tumor-infiltrating tumor-antigen-specific CD8⁺ T cells. *J. Immunol.* **202**, 195.2-195.2 (2019).
20. Pauken, K. & in immunology, W. E. Overcoming T cell exhaustion in infection and cancer. (2015).

- 474 21. Kamphorst, A. O. *et al.* Rescue of exhausted CD8 T cells by PD-1–targeted therapies is
475 CD28-dependent. **355**, 1423–1427 (2017).
- 476 22. Wherry, E. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. *Nat Rev*
477 *Immunol* **15**, 486–99 (2015).
- 478 23. Seliktar-Ofir, S. *et al.* Selection of Shared and Neoantigen-Reactive T Cells for Adoptive
479 Cell Therapy Based on CD137 Separation. *Front. Immunol.* **8**, 1211 (2017).
- 480 24. Wolfl, M. *et al.* Activation-induced expression of CD137 permits detection, isolation, and
481 expansion of the full repertoire of CD8+ T cells responding to antigen without requiring
482 knowledge of epitope specificities. *Blood* **110**, 201–210 (2007).
- 483 25. Borst, J., Ahrends, T., Bąbala, N., Melief, C. J. M. & Kastenmüller, W. CD4 + T cell help in
484 cancer immunology and immunotherapy. *Nat. Rev. Immunol.* **18**, 635–647 (2018).
- 485 26. Friedman, K. M. *et al.* Tumor-specific CD4+ Melanoma Tumor-infiltrating Lymphocytes. *J.*
486 *Immunother.* **35**, 400–408 (2012).
- 487 27. Hunder, N. N. *et al.* Treatment of Metastatic Melanoma with Autologous CD4+ T Cells
488 against NY-ESO-1. *N. Engl. J. Med.* **358**, 2698–2703 (2008).
- 489 28. Tran, E., Turcotte, S., Gros, A., Robbins, P. & Lu, Y. Cancer immunotherapy based on
490 mutation-specific CD4+ T cells in a patient with epithelial cancer. (2014)
491 doi:10.1126/science.1251102.
- 492 29. Simon, S. & Labarriere, N. PD-1 expression on tumor-specific T cells: Friend or foe for
493 immunotherapy? *Oncoimmunology* **7**, (2017).
- 494 30. Thommen, D. S. & Schumacher, T. N. T Cell Dysfunction in Cancer. *Cancer Cell* **33**, 547–
495 562 (2018).
- 496 31. Kamphorst, A. O. *et al.* Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–
497 targeted therapy in lung cancer patients. *Proc. Natl. Acad. Sci.* **114**, 4993–4998 (2017).

- 498 32. Longoria, T. C. & Eskander, R. N. Immune checkpoint inhibition: therapeutic implications in
499 epithelial ovarian cancer. *Recent Patents Anticancer Drug Discov.* **10**, 133–144 (2015).
- 500 33. Segal, N. H. *et al.* Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-
501 CD137 Monoclonal Antibody. *Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.* **23**, 1929–
502 1936 (2017).
- 503 34. Segal, N. H. *et al.* Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-
504 1BB/CD137 Agonist, in Patients with Advanced Cancer. *Clin. Cancer Res. Off. J. Am.*
505 *Assoc. Cancer Res.* **24**, 1816–1823 (2018).
- 506 35. Gaspar, M. *et al.* CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is
507 Dependent on Target Coengagement. *Cancer Immunol. Res.* **8**, 781–793 (2020).
- 508 36. Lakins, M. A. *et al.* FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low
509 Toxicity and Antitumor Activity in Colorectal Cancer Models. *Clin. Cancer Res.* **26**, 4154–
510 4167 (2020).
- 511 37. Zamarin, D. *et al.* Randomized Phase II Trial of Nivolumab Versus Nivolumab and
512 Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study. *J. Clin.*
513 *Oncol.* **38**, 1814–1823 (2020).
- 514

Figure 1

Figure 2

Figure 3

Figure 4

A bioRxiv preprint doi: <https://doi.org/10.1101/2021.03.29.437255>; this version posted March 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Figure 5

Figure 6